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RESEARCH ARTICLES
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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease; survival in ALS is typically 3–5
years. No treatment extends patient survival by more than three months. Approximately 20% of familial
ALS and 1–3% of sporadic ALS patients carry a mutation in the gene encoding superoxide dismutase 1
(SOD1). In a transgenic ALS mouse model expressing the mutant SOD1G93A protein, silencing the SOD1
gene prolongs survival. One study reports a therapeutic effect of silencing the SOD1 gene in systemically
treated adult ALS mice; this was achieved with a short hairpin RNA, a silencing molecule that has raised
multiple safety concerns, and recombinant adeno-associated virus (rAAV) 9. We report here a silencing
method based on an artificial microRNA termed miR-SOD1 systemically delivered using adeno-associated
virus rAAVrh10, a serotype with a demonstrated safety profile in CNS clinical trials. Silencing of SOD1 in
adult SOD1G93A transgenic mice with this construct profoundly delayed both disease onset and death in
the SOD1G93A mice, and significantly preserved muscle strength and motor and respiratory functions. We
also document that intrathecal delivery of the same rAAVrh10-miR-SOD1 in nonhuman primates sig-
nificantly and safely silences SOD1 in lower motor neurons. This study supports the view that rAAVrh10-
miR-SOD1 merits further development for the treatment of SOD1-linked ALS in humans.
INTRODUCTION
AMYOTROPHIC LATERAL SCLEROSIS (ALS) is a devas-
tating, invariably fatal neurological disease caused
by degeneration of the motor neuron system lead-
ing to often rapidly progressing paralysis. It has an
incidence of about 1.5–2.5 cases in 100,000 persons
in the general population in the United States1,2
and in Europe,3 or up to about 30,000 new cases of
ALS per year in those areas. The average life ex-
pectancy in ALS ranges from three to five years
postdiagnosis. There is no cure for ALS, and the
only FDA-approved treatment to date extends
survival by only about three months.4
Familial ALS, which represents about 10% of all
ALS cases, is inherited as a dominant trait, and of
these cases approximately 20% arise from mutations
in the gene encoding Cu/Zn cytosolic superoxide dis-
mutase 1 (SOD1).5 An estimated 12–23% of familial
ALS and 1–3% of sporadic ALS patients carry a mu-
tation in this gene; 183 mutations inSOD1have been
identified (ALS online genetics database). The precise
mechanisms whereby mutant SOD1 proteins are
neurotoxic are not fully defined. Evidence suggests
that mutant SOD1 acquires toxicity via conforma-
tional instability, misfolding, and some degree of ag-
gregation.6 In turn, this activates multiple adverse
events that include the unfolded protein response,7
endoplasmic reticulum (ER) stress,8 mitochondrial
damage,9 heightened cellular excitability,10 impaired
axonal transport,11 and some elements of apoptotic12
and necrotic13 cell death. Some data suggest that the
misfolded mutant SOD1 protein can spread from cell
to cell in a prion-like fashion.14 Mutant SOD1 can
cause toxic misfolding of wild-type SOD1.12,15
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Multiple studies have robustly documented that
silencing expression of the mutant SOD1 protein
prolongs survival of SOD1-linked ALS mice. Ap-
proaches to silence SOD1 have included shRNA,16
transgene-delivered shRNA,17 antisense oligonucle-
otides,18 and virally delivered silencing elements.
Initial viral delivery studies achieved successful
attenuation of SOD1 using a lentivirus.19,20 More
recent studies have employed recombinant adeno-
associated virus (rAAV), which is now the viral vec-
tor of choice for many gene therapy approaches.
A 2013 study showed that silencing SOD1 in the
high-copy transgenic SOD1G93A mouse with an
rAAV9-shRNA delayed onset and increased survival
in mice treated at birth; treatment at later stages
also prolonged survival, but without delaying on-
set.21 The same group later demonstrated the effi-
cacy of this approach in rats, showing that silencing
SOD1 in the upper motor neurons also prolonged
survival.22 More recently, rAAV6 and rAAV9 vec-
tors expressing an artificial microRNA (miRNA)
against SOD1 were also shown to prolong survival
in P2-treated reduced-copy SOD1G93A mice,23 and
the survival benefit was 26% with rAAV6 and 14%
with rAAV9, a much more modest result than had
been obtained in P1-treated animals by Foust et al.21
In the rAAV6/rAAV9 study, no increase in survival
or delay in onset was shown when the reduced-copy
SOD1G93A mice were treated as early adults
(P35).23 Finally, an rAAVrh10 vector expressing
an artificial miRNA against SOD1 extended sur-
vival of adult SOD1G93A mice (with a reduced
transgene copy number) by about 11% when de-
livered intrathecally, but did not delay onset or
showed any improvement in motor function.24
The current study was designed to optimize the
efficacy of rAAV-mediated RNAi as a treatment
for SOD1-linked ALS in adult mice with the ex-
pectation that this approach would be clinically
applicable. An artificial miRNA molecule was se-
lected to induce silencing. Its expression and effi-
cacy in SOD1 silencing were quantified using two
constructs that compared polymerase II (pol II) to
polymerase III (pol III) promoters. These constructs
are packaged in rAAVrh10, which was selected both
because it demonstrated excellent CNS transduc-
tion24 and because it has proven to be safe when
delivered to the CNS in humans.25 In the present
study, we have delivered the therapy to adult ALS
mice (P56–68 high-copy SOD1G93A mice) and adult
nonhuman primates via intrathecal administra-
tion, employing a paradigm that may ultimately be
useful as a therapy for mutantSOD1-mediated ALS
in humans. This proof-of-concept study documents
that expressing miR-SOD1 from a pol II or a pol III
promoter significantly prolongs survival after de-
livery in adult mice, and demonstrates feasibility of
intrathecal delivery of the same vector in the non-
human primate (NHP) Callithrix jacchus.
MATERIALS AND METHODS
In vitro validation
Human embryonic kidney cells (HEK293, 1E6)
were transfected with 2lg plasmid DNA (Jetprime;
PolyPlus) and were harvested at 48 hr posttrans-
fection; total RNA was isolated (Trizol; Life Tech-
nologies) and SOD1 transcripts were quantified
by RT-qPCR. Experiments were carried in biolog-
ical triplicates. HEK293 were transfected with 4 lg
plasmid DNA (Lipofectamine 2000; Life Technolo-
gies) and were harvested at 72 hr posttransfec-
tion; Western blot was performed as described
previously.26
Constructs
For the in vivo studies, three constructs were
used: a control vector expressing GFP only and
two vectors expressing miR-SOD1 driven by ei-
ther a polymerase II (pol II) or a pol III promoter.
The control (CB-GFP) construct is composed of the
CMV enhancer, chicken beta-actin promoter (CB)
containing the Promega intron, green fluorescent
protein (GFP) gene, BGH poly A termination sig-
nal. The CB-miR-SOD1 construct contains the
same CB-GFP cassette, with the addition of two
copies of the artificial miRNA designed to target
human SOD1 (miR-SOD1) located within the first
intron of the GFP gene. The U6-miR-SOD1 con-
struct contains a first cassette composed of the
CMV enhancer, CB promoter containing the SV40
and not the Promega intron, GFP, SV40 poly A,
and a second cassette composed of the U6 pro-
moter upstream of one copy of miR-SOD1. The
same constructs/vector batches were used for the
murine experiments.
Viral vectors and vector batches validation
before NHP study
rAAVrh10 vectors were produced, and vector
particles and vector genome copies (gc) were quan-
tified by the University of Massachusetts Medical
School Vector Core. Titers were quantified simul-
taneously for all batches.
Before the NHP experiment, vector batches were
tested in SOD1G93A mice for SOD1 silencing. The
mice (n = 3 per group) received 2E11 gc of vector
intravenously through the lateral tail vein, and
liver SOD1 and Sod1 knockdown were assessed by
RT-qPCR at 2 weeks postinjection (Supplementary
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Fig. S1; Supplementary Data are available online
at www.liebertpub.com/hum).
Animal experiments
All murine experiments were performed at the
University of Massachusetts Medical School and
were approved by the Institutional Review Board.
Male and female adult (P50–68) high-copySOD1G93A
mice (B6SJL.SOD1-G93A; Supplementary Table S1)
received 200ll of vector intravenously through the
lateral tail vein for a total dose of 2E12 gc per animal,
and were euthanized upon blinded assessment of
advanced paralysis by an experienced animal care-
taker. Disease onset was defined as peak body weight
(as a consequence of weight loss from denervation-
induced muscle atrophy), and disease duration as the
period between disease onset and euthanasia. For all
these parameters, significance was determined with
a log-rank (Mantel–Cox) test. Mice from the CB co-
hort were obtained from the Jackson Laboratory
through Prize4Life. Mice from the U6 cohort were
bred in-house and transgene copy number was veri-
fied by RT-qPCR (Supplementary Table S1) accord-
ing to the Jackson Laboratory guidelines: mice with a
copy number deviating more than 0.5 Ct from the
calibrator were excluded, equivalent to a 16.75–33.25
copy number range.
The C. jacchus experiment was performed at the
Harvard Primate Center and was approved by the
Institutional Review Board. Marmosets were pre-
screened for neutralizing antibody (NAb) levels
against AAVrh.10 by the University of Massachu-
setts Medical School Vector Core. In addition, all
animals were of similar age (less than 4 years old)
and body weight (353–476 g). They received 300ll of
vector intrathecally at lumbar level for a total dose of
6E12 gc/kg body weight. Tail flick reflex was moni-
tored to confirm proper placement of the needle. The
animals were euthanized 18–23 days postinjection.
Physiology measurements
Rotarod. Before measurements, mice were
trained on an accelerating rod (Med Associates Inc.)
until they could remain on the apparatus for 1 min
without falling. They were then subjected to rotarod
testing on a biweekly basis. The latency to fall from
the apparatus was recorded for a duration of 5 min.
Three trials were performed for each animal and the
longest time taken to fall was recorded.
Grip strength. Two and four limbs’ muscle stre-
ngth was determined by measuring peak force us-
ing a digital grip strength meter (Mark-10
force gauge model M4-2) equipped with a hind limb
pull bar. Mice were allowed to grip the metal grids,
and gently pulled backward by the tail until they
could no longer hold the grids. The grip force was
observed over 3 trials and the maximum force was
recorded. Ventilation was quantified using whole-
body plethysmography in unrestrained, unanesthe-
tized mice as previously described.27–29 Briefly, mice
were placed inside a 3.5† ·5.75† Plexiglas chamber,
which was calibrated with known airflow and pres-
sure signals before data collection (EMKA Inc.). Data
were collected in 10 sec intervals, and the Drorbaugh
and Fenn equation30 was used to calculate respira-
tory volumes, including tidal volume and minute
ventilation. The plethysmography is used with IOX2
software (EMKA Inc.). During both a 30 min accli-
mation period and subsequent 30–60 min baseline
period, mice were exposed to normoxic air (21% O2,
79% N2). At the conclusion of the baseline period, the
mice were exposed to a brief respiratory challenge,
which consisted of a 10 min exposure to hypercapnia
(7% CO2, 21% O2, balance N2). Experiments were
conducted on paired control and treated animals
(n = 7). For all the physiological parameters, sig-
nificance was determined with a two-way ANOVA.
Immunostaining of NHP tissue
Agarose-embedded fixed spinal cord tissue was
sectioned at 40 lm and floating sections were im-
munostained for GFP. Briefly, the endogenous
peroxidases were saturated for 15 min in 0.5%
H2O2, 10% methanol. The tissue was then per-
meabilized and blocked for 1 hr in 1% Triton X-100
and 10% normal goat serum (ab7481; Abcam).
Sections were incubated in a 1:2000 dilution of
primary antibody (anti-GFP antibody ab13970;
Abcam) for 5 days at 4C, then in a 1:400 dilution
of secondary antibody (Biotinylated Goat Anti-
Chicken IgG Antibody, BA-9010; Vector Labs)
for 2 hr at room temperature, then in the avidin/
biotinylated enzyme complex (Vectastain Elite ABC
kit; Vector Labs PK-6105) for 1 hr at room tem-
perature, and finally in the peroxidase substrate
(NovaREDd kit Peroxidase Substrate Kit, SK-
4800; Vector Labs). Tissue sections were then de-
hydrated and mounted before imaging on a Leica
DM5500B using Leica Application Suite (Leica
Microsystems).
Laser-capture microdissection of motor
neurons and RNA isolation
Laser-capture microdissection of motor neurons
was performed by an experienced technician at the
Harvard NeuroDiscovery Center (*2000 cells per
section per animal). RNA was subsequently iso-
lated using Ambion RNAqueous-Micro kit (Life
Technologies).
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RT-qPCR
First-strand cDNA was synthesized with the
High Capacity RNA-to-cDNA kit (Life Technolo-
gies). Commercial hsa SOD1 and hsa HPRT were
used for the in vitro validation, and hsa SOD1 and
mmuHprtTaqMan assays were used for the murine
experiment. Custom primers and FAM-labeled
probes were designed for detection of C. jacchus
SOD1 and HPRT mRNA, but not gDNA. A custom
small RNA TaqMan assay was designed for detec-
tion of mature miR-SOD1, and a commercially
available assay was used for detection of snoRNA-
135 (primer and probe sequences or commercial
references available in Supplementary Table S2).
All TaqMan assays and master mixes were ordered
from Life Technologies and used according to the
manufacturer’s recommendations. RT-qPCR data
were analyzed with the DDCt method.31
RNA multiplexed branched fluorescent
in situ hybridization
Frozen spinal cord tissue was cryosectioned at a
thickness of 20lm. Multiplexed branched fluores-
cent in situ hybridization was performed according
to the manufacturer’s recommendations (ACDbio).
Briefly, the sections were fixed for 15 min at 4C
in 10% neutral-buffered formalin and pretreated
with a protease-based solution for 30 min at room
temperature to increase availability of the target
mRNA. DNA probes were hybridized with the tar-
get mRNAs (GFP in C1, Alexa488;SOD1 in C2, Atto
550; ChAT in C3, Atto 647) for 1 hr at 40C and
bound probe signal was subsequently amplified
through branching before imaging on a Leica
DM5500B using Leica Application Suite.
Biodistribution in NHP
Genomic DNA (gDNA) was isolated (DNeasy
Blood and Tissue kit; Qiagen) from frozen tissue
and ddPCR (Biorad) was performed according to
the manufacturer’s recommendations using 50 ng
of DNA as input and TaqMan assays detectingGFP
and Cja albumin (Supplementary Table S2).
Neutralizing antibody response to AAVrh.10
Serum sampled before injection and at weeks 1
and 3, and CSF sampled at week 3 were heat-
inactivated for 30 min at 56C. AAVrh.10-CMV-
LacZ (3E8 gc/well) was incubated with 2-fold serial
dilutions of the samples for 1 hr at 37C, 5% CO2.
The mixture was then added to 1E5 Huh7 cells
previously infected with an adenovirus (100 vp/
well) and incubated for 18–22 hr at 37C, 5% CO2.
Cells were washed and developed with Galactor-
Star kit (Life Technologies). Luminescence was
measured with a luminometer (Synergy HT, Bio-
tek). The NAb titers are expressed as the highest
dilution that inhibited b-galactosidase expression
by at least 50% compared with a negative mouse
serum control (M5905; Sigma-Aldrich).
RESULTS
Design of an artificial miRNA (miR-SOD1)
that is highly efficient in vitro
The artificial miRNA miR-SOD1 was designed
based on the backbone of cellular miR-155 (Fig. 1a).
For the in vitro validation, plasmid DNA was
transfected into HEK293 cells. Substantial reduc-
tion in SOD1 mRNA (Fig. 1b) and protein levels
(Fig. 1c) was verified at 48 and 72 hr posttransfec-
tion, respectively. Because it targets a conserved
sequence in the SOD1 gene, miR-SOD1 also rec-
ognizes the marmoset mRNA sequence (Fig. 1d).
Administration of miR-SOD1 to adult
SOD1G93A mice significantly delays disease
onset and extends survival
To determine if miR-SOD1 is effective in vivo
after rAAV-mediated delivery, we tested it in
SOD1G93A mice in experiments that compared the
efficacy of pol II (chicken beta actin or CB) and pol
III (U6) promoters. With either promoter, intra-
venous rAAVrh10-mediated delivery through the
tail vein of miR-SOD1 to adult (P56–68), pre-onset
SOD1G93A mice extends survival (Fig. 2). A signif-
icant extension in survival (22 days, or 20%, n =14–
22, p =0.0485) is observed (Fig. 2a) in the group
treated with the CB-driven construct (130 days),
compared with an age-matched, gender-matched
control group (108 days). Survival is prolonged to a
greater extent by the CB-miR-SOD1 treatment in
the subset of females (34 days, or 32%, n =8–10,
p= 0.0076; data not shown). A more robust exten-
sion of survival (27 days, or 21%, n = 15–17,
p< 0.0001) is observed (Fig. 2b) in the group treated
with the U6-driven construct (158 days) compared
with age-matched, gender-matched littermates
(131 days). Such extension in survival is similar to
that observed in the only study reporting systemic
treatment of adult SOD1G93A mice, which was 23%
using rAAV9-shRNA.21 No signs of toxicity were
observed in either group, based on daily assess-
ment of discomfort as well as spinal cord Hprt
levels by RT-qPCR.
For the CB-driven construct, the delay in disease
onset of 11 days (12.5%) was not statistically sig-
nificant (88 days for the control group vs. 99 days
with treatment; Fig. 2c). By contrast, the U6-
driven construct did achieve a significant 31-day
(31%) delay in onset (from 100 to 131 days, n =15–
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17, p<0.0001) for the treated group (Fig. 2d). This
exceeds all studies reporting treatment of early
adult23 and adult SOD1G93A mice,21,24 where no
delay in disease onset was reported. This delay in
onset is documented in mice at 144–145 days of age,
which is passed median survival of untreated
SOD1G93A mice (Supplementary Videos S1 and S2).
Disease duration was extended by treatment
with the CB-miR-SOD1 construct from 18 to 35 days
(94%, p = 0.0015; Fig. 2e). A similar disease dura-
tion was observed for the U6-miR-SOD1-treated
(34 days) and the untreated (33 days) group (Fig. 2f),
indicating that the increased survival observed
in this group can be attributed primarily to a delay in
onset.
Administration of miR-SOD1 to adult
SOD1G93A mice significantly preserves limb
strength and motor skills, and stabilizes
respiratory physiology
A significant preservation in two and four
limbs’ strength was observed (Fig. 3a and b), in-
dicating that the treatment efficiently delays
muscle wasting (p< 0.0001 for both parameters).
Moreover, the treatment significantly preserved
motor skills as assessed by rotarod performance
test (p=0.0028), where there is a remarkable
difference in latency to fall in mice 120 days of age
and older (Fig. 3c).
During the normoxic baseline conditions, the U6-
miR-SOD1-treated and the untreated SOD1G93A
mice showed similar tidal volume, peak inspira-
tory flow, minute ventilation, and breathing fre-
quency (Fig. 3d–g). However, during a 10 min
hypercapnic respiratory challenge, the breath-
ing pattern of the treated SOD1G93A mice demon-
strated a larger tidal volume and minute ventilation
(Fig. 3d; p=0.0043 and Fig. 3f; p=0.0137) as com-
pared with the control group. In addition, treated
mice had a more robust peak inspiratory flow in-
dicative of inspiratory muscle strength (Fig. 3e;
p=0.0455) as compared with controls. There was no
significant difference in frequency between the two
groups (Fig. 3g; p=0.1208).
Figure 1. Design and in vitro validation of miR-SOD1, an artificial miRNA targeting human SOD1. (a) miR-SOD1 was designed to have perfect
complementary to human SOD1, and is based on the backbone of cellular miR-155. (b) HEK293 cells were transfected with 2 lg plasmid DNA. Cells
were harvested at 48 hr posttransfection and RNA was isolated. SOD1 and HPRT transcripts were quantified by RT-qPCR. Relative SOD1 expression
was calculated according to the DDCt method, and three biological replicates were analyzed. Data are presented as average of the replicates – SEM.
(c) HEK293 cells were transfected with 4 lg plasmid DNA and cells were harvested and lysed at 72 hr posttransfection. Equal amounts of protein were
run on an SDS-PAGE and incubated with anti-SOD1 (red) and anti-beta-actin (green) antibodies. (d) Alignment showing perfect complementarity
between the human (Hsa) and the marmoset (Cja) mRNA sequences at the mature miR-SOD1 site, but only partial complementarity with the endogenous
mouse mRNA sequence (Mmu) in particular including two mismatches within the seed sequence at position 4 and 7. miRNA, microRNA; SOD1,
superoxide dismutase 1.
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Lumbar intrathecal rAAVrh10-mediated
delivery of miR-SOD1 silences SOD1
along the entire spinal cord in C. jacchus
The marmoset (C. jacchus) is a New World pri-
mate that is commonly used in neuroscience re-
search because of its small size, high birth rate, and
easy handling32; other advantages include efforts
toward mapping of the marmoset brain,33 as well
as the successful generation of transgenic marmo-
sets.34 Marmosets have been used in studies for
Huntington’s,35 Parkinson’s,36,37 and Alzheimer’s
diseases.38,39 We elected to use marmosets for
studies of intrathecal delivery of rAAVrh10-miR-
SOD1. Nine marmosets of comparable age and
body weight, and prescreened for low levels of NAb
against AAVrh.10, received an intrathecal injec-
tion at lumbar level of 6E12 gc/kg body weight in
300ll total volume of rAAVrh10 encoding one of
the three constructs previously described: CB-
GFP, CB-miR-SOD1, and U6-miR-SOD1. Tail-flick
response was monitored as a sign of proper needle
placement, indicative of piercing of the dura and
contact with intradural nerve roots. The animals
were split into three groups of three, each gender-
matched (Supplementary Table S3). They were
euthanized at 18–23 days postinjection to avoid
possible immune response to the GFP. Tissues
from one animal from each group were fixed upon
Figure 2. Reducing SOD1 expression prolongs survival in SOD1G93A mice. SOD1G93A mice were injected intravenously through the tail vein with 2E12 gc vector
and were monitored daily by an experienced, blinded animal caretaker until they were euthanized. The mice were treated with either (a) the CB-driven miR-
SOD1 or (b) the U6-driven miR-SOD1. (a) Median survival is 108 days for the control group and 130 days for the CB-miR-SOD1 group, p= 0.0485. (b) Median
survival is 131 days for the control group and 158 days for the U6-miR-SOD1 group, p< 0.0001. (c) Disease onset is 88 days for the control group and 99 days for
the CB-miR-SOD1 group. (d) Disease onset is 100 days for the control group and 131 days for the U6-miR-SOD1 group, p < 0.0001. (e) Median disease duration
was 18 days for the control group and 35 days for the CB-miR-SOD1 group, p= 0.0015. (f) Median disease duration was 34 days for the control group and
33 days for the U6-miR-SOD1 group. Statistical analysis of the survival, onset, and disease duration data was performed (log-rank test).
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Figure 3. Reducing SOD1 expression preserves limb strength and motor skills, preserves motor neurons, and improves respiratory physiology. Limb strength
was quantified by grip strength test for two (a) or four limbs (b). Motor skills of SOD1G93A mice were assessed by rotarod performance test (c). Respiratory
physiology was assessed at baseline (dotted lines) and during hypercapnia (fill lines), including tidal volume (d), peak inspiratory flow (e), minute ventilation
(f), and frequency (g).
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euthanasia and used for immunostaining; tissues
from the other two animals from each group were
frozen upon euthanasia and used for all other end
points. The females were subsequently excluded
from all further analyses, based on absence of tail-
flick response upon needle placement questioning
the efficacy of the delivery, which was later con-
firmed by low GFP levels as determined by RT-
qPCR to be significantly lower than in the males.
Biodistribution studies demonstrated that, as
expected, the highest number of genome copies per
diploid genome (gc/dg) was found at the site of in-
jection in the lumbar spinal cord, varying from
25.07 to 227.45 gc/dg (Supplementary Fig. S2). In
the thoracic spinal cord, 16.46–122.93 gc/dg were
detected, and 0.63–29.19 gc/dg in the cervical spi-
nal cord (Supplementary Fig. S2). The second
highest tissue was the liver with a range of 44.42–
138.18 gc/dg (Supplementary Fig. S2). Vector ge-
nomes were also detected in the brain with values
ranging from 0.08 to 7.73 gc/dg, although a limited
number of samples was available for biodistribu-
tion (Supplementary Fig. S2).
In addition, CNS transduction was evaluated by
immunostaining for GFP. Robust GFP staining
was seen at the injection site at LSC level all the
way to CSC level (Fig. 4a–c), confirming that this
delivery route allows vector delivery to the entire
spinal cord. Motor neurons (as distinguished based
on morphology) stained positive for GFP at all
levels of the spinal cord (Fig. 4d–f). As shown in
Fig. 6, GFP expression was detected in motor
neurons that were positive for both SOD1 and
ChAT as determined by RNA expression.
Figure 4. NHP motor neurons are transduced by rAAVrh10. (a–f) Fixed spinal cord tissue was sectioned at 40 lm and incubated with an anti-GFP antibody.
Representative images are presented here, with (d–f) being a higher magnification of (a–c) showing specifically the motor neuron-rich ventral horns. (g–i)
Frozen spinal cord tissue was sectioned at 20 lm and motor neurons were laser-captured by an experienced technician. Both motor neurons (i) and non-motor
neurons tissue (h) were harvested. NHP, nonhuman primate; rAAV, recombinant adeno-associated virus.
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Next, SOD1 silencing was evaluated in the spi-
nal cord. Motor neurons (n&2,000) were isolated
from 20lm sections (Fig. 4g) by laser-capture mi-
crodissection (Fig. 4g–i); total RNA was isolated
from motor neurons (Fig. 4i) and nonmotor neuron
tissue (Fig. 4h). SOD1 mRNA levels were quanti-
fied by RT-qPCR (Fig. 5a–f). In motor neurons
(Fig. 5a–c),SOD1 levels are decreased with the CB-
miR-SOD1 by 21% in the lumbar region and 8% in
the cervical region (thoracic region data not avail-
able). With the U6-miR-SOD1 construct, SOD1
levels are decreased by 93% in the lumbar, 65% in
the thoracic, and 92% in the cervical cord region
(Fig. 5a). Similar levels of silencing were observed
in the nonmotor neuron tissue (Fig. 5d–f). To con-
firm that the observed reduction in SOD1 mRNA
was miRNA-mediated, mature miR-SOD1 levels
were quantified by RT-qPCR (Fig. 5g). Levels in the
LSC motor neurons of the U6-miR-SOD1-injected
animal were four times higher than in the motor
neurons of the CB-miR-SOD1-injected animal.
Background levels of mature miR-SOD1 were de-
tected in the CB-GFP animal, possibly attributable
to contamination during tissue harvesting (Fig. 5g).
The levels of SOD1 silencing positively correlated
with the levels of mature miR-SOD1 expression
(R2 = 0.99). This analysis was only done in the LSC
as limited material was available. SOD1 levels
were next evaluated in the pons and medulla by
RT-qPCR. In total tissue homogenates, SOD1
Figure 5. SOD1 silencing in NHP motor neurons and pons/medulla correlates positively with the levels of mature miR-SOD1. SOD1 and HPRT transcripts were
quantified by RT-qPCR in spinal cord motor neuron (a–c), non-motor neuron (d–f), and pons/medulla (g) tissue. Mature miR-SOD1 and snoRNA-135 small
RNAs were quantified by RT-qPCR in lumbar spinal cord motor neuron and positively correlated with SOD1 silencing (h). Spinal cords were sectioned into
lumbar (a, d, and h), thoracic (b and e), and cervical (c and f). Relative SOD1 expression and miR-SOD1 expression were calculated according to the DDCt
method. control, CB-GFP vector; ND, nondetected.
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levels are decreased by 20% with the CB-miR-
SOD1 construct, and by 35% with the U6-miR-
SOD1 construct (Fig. 5h).
Subsequently, RNA multiplex fluorescent in situ
hybridization was performed, using aGFP probe in
C1 to mark transduced cells, and a SOD1 probe in
C2 and a ChAT probe in C3 to mark cholinergic
neurons, including motor neurons (Fig. 6). Positive
ChAT staining as well as cell morphology were
used here for identification of motor neurons in
ventral horns. The CB-GFP animal had low levels
of GFP and high levels of SOD1 in motor neurons
(Fig. 6a and b). The CB-miR-SOD1 animal pre-
sented similar fluorescence (data not shown).
Consistent with efficient SOD1 silencing, the spi-
nal cord sections in the U6-miR-SOD1 animal had
high levels of GFP and low or background levels
of SOD1 in motor neurons (Fig. 6c and d). The se-
lected images are representative. The marked dif-
ference in fluorescence between the treated and
nontreated animals is consistent with the RT-
qPCR data and confirms thatSOD1 expression was
substantially attenuated in the motor neuron
population.
Preexisting NAb response to AAV has a critical
impact on transduction efficiency after vector in-
jection. Therefore, NHPs were screened for NAb to
rAAVrh10 before injection and only NHP present-
ing NAb titers lower than 1:5 were selected to
prevent any rAAV vector neutralization. Serum
samples were then collected 1 week and 3 weeks
after vector administration. Consistent with re-
sults already published after IC or IT rAAV injec-
tion,40 NAb to injected rAAVrh10 vector were
detected in all NHPs (Supplementary Table S4).
The NAb titers detected at week 1 ranged from
Figure 6. SOD1 mRNA is undetectable in GFP-positive, ChAT-positive motor neurons of animal treated with U6-miR-SOD1. Twenty-micrometer sections of
frozen spinal cord tissue, from either the control animal (a and b) or the U6-miR-SOD1 animal (c and d), were incubated with multiplexed probes detecting GFP
(green), SOD1 (yellow), and ChAT (red) mRNAs. The nuclei were stained with DAPI (blue). Two representative images from different sections are shown for
each animal. The scale bar represents 25 lm.
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1:80 to 1:640 and then increased between week 1
and week 3 (range 640–1280). We also measured
NAb titers in CSF collected at 3 weeks after AAV
administration. In contrast to the results obtained
in the serum at the same time point, the titers were
significantly lower (range 1:5–1:40) with the ex-
ception of NHP No. 18, which had a titer of 1:160.
DISCUSSION
Previous studies have shown that viral vectors
permit CNS delivery of constructs that reduce ex-
pression of the SOD1 gene and thereby extend
survival of transgenic SOD1G93A ALS mice. In
particular, this was shown with lentivirus20 and
rAAV6 and rAAV921,23 in SOD1G93A mice and with
rAAV9 in SOD1G93A rats.22 In the only study in
which adult mice (defined as >50 days) were trea-
ted with rAAV expressing an artificial miRNA, the
treated animals survived 11% longer, and disease
onset was not delayed.24 Here we report extending
survival by 20% (22 days) with pol II-miR-SOD1
and 21% (29 days) with pol III-miR-SOD1, and we
also report delaying disease onset by 31% (31 days)
with the pol III, but not with the pol II. Finally,
whereas disease duration is not affected by the U6-
miR-SOD1 treatment, the CB-miR-SOD1 signifi-
cantly slows down disease progression. Although
the two studies were done at different times, the
experimental protocol was identical, and it is not
clear why a change of promoter would lead to such
difference, and will be further investigated. The
male/female ratio is also different in each study
and may account for the difference. The strength of
the murine study lies in the robust preservation of
two and four limbs’ strength, rotarod performance,
and ventilation, which support our survival data.
Interestingly, although the respiratory phenotype
of the SOD1G93A mice has been characterized as
early as 2006,41 to our knowledge no therapy has
ever reported to slow down or stabilize the respi-
ratory phenotype in these mice. Because the mice
recapitulate the respiratory phenotype of ALS pa-
tients, these results highlight the potential of the
proposed therapy for clinical use.
Another difference in this study is that we used
an artificial miRNA to reduce SOD1 expression,
whereas most of the previous studies used shRNA.
This allowed us to do a promoter comparison that
had never been done in this context. Pol II- and pol
III-driven artificial miRNAs present a number of
advantages over pol III-driven shRNAs, including
improved safety. This is thought to be related to
the accuracy of the processing of the miRNA over
the shRNA hairpin molecule.42 As mentioned pre-
viously, no toxicity was observed in the current
study; in addition to the use of an artificial miRNA,
this may also reflect the fact that we used lower
vector doses than in prior studies reporting toxici-
ty.43,44 Nevertheless, the lack of toxicity in this
study is noteworthy given that CNS-related toxicity
has been reported on various occasions.42,45–49 Al-
though in the NHP robust silencing was observed
only with the U6-driven construct, optimization of
the expression cassette and delivery technique may
improve knockdown with the CB-driven construct.
Our study is also distinguished by the use of
serotype rh.10 instead of rAAV9 and rAAV6. Al-
though it was shown that rAAV9 transduces motor
neurons after systemic injection of a newborn
NHP,50 intrathecal delivery of rAAV9 in NHPs lead
primarily to transduction of astrocytes.51 The use
of rh.10 is a point that may be favorable in this case
where motor neurons are the primary target. In-
deed, we demonstrate here excellent transduction
of motor neurons. From an epidemiological per-
spective, the use of rh.10 over 9 would not be
disadvantageous; the prevalence of NAb is equiv-
alent for both serotypes.52 In addition, several
clinical trials with rAAVrh10 are currently ongoing
(NCT01414985, NCT01801709, NCT01161576,
and NCT02168686); this should generate further
safety data for this AAV capsid.
In this proof-of-concept, translational study, an-
other critical issue is the method of delivery of
the viral vector; this is particularly important in
considering the transition from rodents to a large-
animal model. We report here that lumbar intra-
thecal delivery of an rAAVrh10 vector allows
excellent transduction of motor neurons all along
the entire spinal cord, extending rostrally into the
distal brainstem. It is clear that this approach,
when coupled with an appropriately active pro-
moter, results in substantial reduction of SOD1
expression. A major obstacle encountered in this
study was the technical challenge of the intra-
thecal delivery, leading to a high rate of failure (3/
9 animals); this was largely a consequence of the
relatively small size of the marmosets. Our
forthcoming studies will continue to focus on op-
timizing delivery to the cerebrospinal fluid, ex-
amining several variables: (1) using injections
into the cisterna magna in addition to the lumbo-
sacral regions; (2) maintaining the subjects in the
Tredelenburg position postadministration, a
method that improves transduction of the thoracic
and cervical segments of the spinal cord53; (3)
implanting the catheter into the intrathecal space
several days in advance of the infusion, a tech-
nique that will allow healing around the catheter
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entry zone and thereby reduce backflow leakage
during infusion; and (4) using larger NHPs. Al-
though more can be done to refine our delivery
system, this study nonetheless demonstrates the
considerable potential of using rAAVrh10 for in-
trathecal delivery of an miRNA to silence expres-
sion of the SOD1 gene as well as the feasibility of
moving to animals larger than ALS mice or rats.
In our view, this improved intrathecal delivery
protocol will allow us to generate robust and re-
producible data that will support clinical devel-
opment of this therapy for SOD1-mediated ALS.
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